Abstract
Damage to the primary visual cortex causes homonymous visual impairments that appear to benefit from visual discrimination training. However, whether improvements persist without continued training remains to be determined and was the focus of the present study. After a baseline assessment visit, 20 participants trained twice daily in their blind-field for a minimum of six months (median=155 sessions), using a motion discrimination and integration task. At the end of training, a return study visit was used to assess recovery. Three months later, 14 of the participants returned for a third study visit to assess persistence of recovery. At each study visit, motion discrimination and integration thresholds, Humphrey visual fields, and structural MRI scans were collected. Immediately after training, all but four participants showed improvements in the trained discrimination task, and shrinkage of the perimetrically-defined visual defect. While these gains were sustained in seven out of eleven participants who improved with training, four participants lost their improvement in motion discrimination thresholds at the follow-up visit. Persistence of recovery was not related to age, time since lesion, number of training sessions performed, proportion of V1 damaged, deficit size, or optic tract degeneration measured from structural MRI scans. The present findings underscore the potential of extended visual training to induce long-term improvements in stroke-induced vision loss. However, they also highlight the need for further investigations to better understand the mechanisms driving recovery, its persistence post-training, and especially heterogeneity among participants.
Competing Interest Statement
Krystel R. Huxlin is an inventor on US Patent No. 7,549,743. The other authors declare no competing financial interests.
Clinical Trial
NCT04878861
Funding Statement
The project was funded by European Research Council grant to Dr Tamietto (prot. 772953), a British Medical Association Foundation John Moulson Grant and Medical Research Council grant (MR/V034723/1) to H. Bridge. H.E. Willis was supported by the Medical Research Council (MR/N013468/1) and a Waverley Scholarship from The Queens College, Oxford. R.S. Millington-Truby is supported by an NIHR academic clinical fellowship. KRH, BKF and MRC were partially supported by a US National Institutes of Health grant (R01 EY027314) co-funded by the Office of Behavioral and Social Sciences Research (OBSSR) and the National Eye Institute (NEI), as well as by an unrestricted grant from Research to Prevent Blindness (RPB) to the Department of Ophthalmology at the University of Rochester. This research was also supported by the NIHR Oxford Health Biomedical Research Centre (NIHR203316). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from Wellcome (203139/Z/16/Z and 203139/A/16/Z). For the purpose of Open Access, the author has applied a CC BY public copyright license to any author-accepted article version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Sciences Interdivisional Research Ethics Committee of University of Oxford gave ethical approval for this work (R60132/RE001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All anonymised data are available on request from the authors following publication.
